MAM
ALXN

Morse Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Morse Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-12,440
Closed -$1.51M – 141
2017
Q1 		$1.51M Buy
+12,440
New +$1.6M 0.51% 63

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morse Asset Management's ALXN Position: Q2 2017 in Review

Morse Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 12,440 shares — an estimated $1.51M sold.

Morse Asset Management first reported a position in ALXN in Q1 2017 and held it in 1 quarter. The position peaked at $1.51M in Q1 2017. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Morse Asset Management reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Morse Asset Management sold 12,440 Alexion Pharmaceuticals shares in Q2 2017, an estimated $1.51M.
  • Morse Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Morse Asset Management's Alexion Pharmaceuticals position peaked at $1.51M in Q1 2017.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Morse Asset Management's 13F filing for Q2 2017, filed 1 Aug 2017.